CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.

BACKGROUND: Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) located in the Xp22 region have been shown to cause a subset of atypical Rett syndrome with infantile spasms or early seizures starting in the first postnatal months.
METHODS: We performed mutation screening of CDKL5 in 60 female patients who had been identified as negative for the methyl CpG-binding protein 2 gene (MECP2) mutations, but who had current or past epilepsy, regardless of the age of onset, type, and severity. All the exons in the CDKL5 gene and their neighbouring sequences were examined, and CDKL5 rearrangements were studied by multiplex ligation-dependent probe amplification (MLPA).
RESULTS: Six previously unidentified DNA changes were detected, two of which were disease-causing mutations in the catalytic domain: a frameshift mutation (c.509_510insGT; p.Glu170GlyfsX36) and a complete deletion of exon 10. Both were found in patients with seizures that started in the first month of life.
CONCLUSIONS: This study demonstrated the importance of CDKL5 mutations as etiological factors in neurodevelopmental disorders, and indicated that a thorough analysis of the CDKL5 gene sequence and its rearrangements should be considered in females with Rett syndrome-like phenotypes, severe encephalopathy and epilepsy with onset before 5 months of age. This study also confirmed the usefulness of MLPA as a diagnostic screening method for use in clinical practice.

Background

Rett Syndrome (RTT) is a neurodevelopmental disorder characterized by loss of spoken language and hand use, hand stereotypes, and mental retardation [1], and is the second most common genetic cause of severe mental retardation in females [2]. Although mutations in the methyl CpG-binding protein 2 gene (MECP2) can be found in 95–97% of individuals with classical RTT and in 50–70% of those with atypical RTT [1], some patients do not carry mutations in this gene, suggesting the existence of other genetic causes of RTT [3].

The cyclin-dependent kinase-like 5 gene (CDKL5) is located in the Xp22 region and has been found to be associated with atypical RTT with infantile spasms or early seizures starting in the first postnatal months (Hanefeld variant) [4,5]. CDKL5 is composed of 20 coding exons and codes for a protein of 1,030 amino acids [6]. CDKL5 mRNA is highly expressed in the adult human brain, which is indicative of its importance in neuronal function and development [3].

The clinical overlap between patients with mutations in CDKL5 and patients with RTT caused by mutations in MECP2 reflects the fact that these genes belong to the same pathway [7,8]. To date, more than 80 cases of pathogenic CDKL5 mutations have been reported [9], but it is likely that many more exist [7]. The present study investigated mutations in CDKL5 in a cohort of patients with epilepsy and RTT or other RTT-like phenotypes to improve the diagnostic criteria for these patients and to clarify the pathological mechanisms of CDKL5 mutations.

Methods

Patients

Patients were referred to our diagnostic laboratory for investigation of MECP2 gene status. We performed mutation screening of CDKL5 in 60 females from this group who were negative for mutations and large rearrangements in MECP2, and who had current or previous epilepsy, regardless of the age of onset, type, or severity. Among these, eight patients were clinically diagnosed with classic RTT, and one with atypical RTT. Twenty patients were thought to be Angelman-syndrome but they were negative for mutations and deletions in UBE3A, and six presented with autistic features. The spectrum of phenotypes of the remaining patients was heterogeneous but with Rett-like features.

These patients were referred by various paediatric neurologists and clinical geneticists throughout Spain, and were included in the present study after signed informed consent forms were obtained from the patients’ parents.

One hundred DNA samples from anonymous healthy female individuals were used as normal controls for exons 1, 12, 17 and 21 (200 X chromosomes). The samples were obtained from the Basque Centre for Transfusions and Human Tissues. The samples and associated data were processed and released by the Basque Biobank for Research-OEHUN (http://www.biobanco.org) following standard operating procedures with appropriate ethical approval. The control individuals had similar geographic origins to the patients. The whole project was approved by the Ethics Committee of Cruces University Hospital.

Screening for CDKL5 mutations

CDKL5 coding sequences and each intron/exon boundary were amplified by polymerase chain reaction (PCR), using previously described primers [10-12], with slight modifications of the amplification conditions. The PCR products were analysed using conformation-sensitive gel electrophoresis (CSGE), after silver-staining following our protocols [13]. Sequence analysis of genomic fragments with CSGE mobility shifts was carried out on an ABI PRISM 3130xl automated DNA sequencer (Applied Biosystems). Exons 4 and 6 were sequenced directly.

Rearrangements studies

Genomic rearrangements were examined using multiplex ligation-dependent probe amplification (MLPA) kits (P189-A2 and P189-B1, MRC Holland, The Netherlands), according to the manufacturer’s protocols.

RNA isolation and reverse-transcriptase PCR

We used cDNA to study mutations/variations in exons 8 and 12. Total RNA isolation and cDNA synthesis were performed as described previously [13]. The region from exon 8 to exon 12 of CDKL5 was amplified by PCR using the following flanking primers: forward, 5′-CAGAGTACGTTGCCACCAGA-3′ in exon 8; and reverse, 5′-GCAGGCCTACACTCAGGTTC-3′ in exon 12. The primers used to amplify only exon 12 were: forward, 5′-TGCACACCAAAACCTACCAAGC-3′ at the start of exon 12; and reverse, 5′-GAATGGCTACTGTCCATGTGC-3′ at the end of exon 12.

In both cases, the PCR products were directly sequenced on both strands using a BigDye Terminator Kit (Applied Biosystems) in a 3130xl automated sequencer (Applied Biosystems).

X chromosome inactivation

X-chromosome inactivation was studied by examination of the highly polymorphic small tandem repeat within the human androgen receptor gene, using previously described protocols [14].

Results

The pathogenic mutations, variants, and polymorphisms identified in the current study are listed in Table 1. Six of them represent DNA changes not previously described in any of the 10 databases consulted [15-24]. Two of these new changes were pathogenic, disease-causing mutations found in two patients with early-onset epileptic seizures within the first month of life, and were both de novo mutations not present in their parents.

Table 1

CDKL5 mutation/variant identified in this study

Total number of females studied*	Number of DNA variants*	Location	Nucleotide change	Aminoacid change	Domain	Effect	Reference**
60 p	1 p	Exon 8	c.509_510insGT	p.Glu170GlyfsX36	Catalytic	Pathogenic	NEW, this study
60 p	1 p	Exon 10	c.745-?_825 + ?del	----------	Catalytic	Pathogenic	NEW, this study
160 (60p + 100c)	1 p	Exon 12	c.1455_1460delGGCCAA	p.Ala486_Lys487del	C-Ter	Unknown Variation	NEW, this study
160 (60p + 100c)	7 (1p + 6 c)	Exon 17	c.2389 G > A	p.Asp797Asn	C-Ter	Polymorphism	NEW, this study
160 (60p + 100c)	6 (1p + 5 c)	Before exon 1	c.-426 C > G	----------	------	Polymorphism	NEW, this study
60 p	1 p	Intron 6	c.403 + 27A > G	----------	------	Without pathogenic effect	NEW, this study
160 (60p + 100c)	2 (1p + 1c)	Exon 21	c.2995 G > A	p.Val999Met	C-Ter	Polymorphism (SNP: rs35693326)	Nectoux et al. [26] Intusoma et al. [27]
160 (60p + 100c)	6 (2p + 4c)	Before exon 1	c.-391 G > T	----------	------	Polymorphism	Evans et al. [12]
60 p	2 p	Exon 4, 21	c.145 + 17A > G; c. 3003 C > G; c. 3084 G > A	p.His1001His; p.Thr1028Thr	Catalytic, C-Ter	Polymorphism	Tao et al. [28]

*p: Female patients; c: control healthy females.

** New mutations/variants have not been described in any of the 10 Genome databases revised [15-24].

The first of these two new mutations was a pathogenic frameshift mutation in exon 8 (c.509_510insGT; p.Glu170GlyfsX36) producing a truncating protein in the catalytic domain that contains only 206 amino-acids on the 1,030 that has CDKL5 protein. The patient was the first child of healthy parents. She was born in a private clinic, and we were unable to obtain all the details related to the delivery, but established that resuscitation had not been required and the infant’s birth weight was 3,450 g. The infant started to have seizures at 4 weeks of life, with facial flushing, vomiting and crying. The family contacted us when the patient was 11 years old with a clinical diagnosis of RTT, with severe mental and psychomotor retardation, poor social contact, axial hypotonia, spastic tetraparesis and epilepsy refractory to numerous treatments.

The second new mutation was a complete deletion of exon 10 (p.745-?_825 + ?del) detected by MLPA (Figure 1A) and confirmed by cDNA analysis (Figure 1B). Although this was an in-frame deletion, we considered it likely to be pathogenic for several reasons: 1) it was a de novo mutation; 2) all exon deletions from exons 1 to 15 in the genomic databases consulted [16,17,19-21] were pathogenic; 3) it was located within the catalytic domain; and 4) the clinical description of the patient was consistent with that of others with CDKL5 deletions. This patient was referred to the Clinical Genetics Unit at 4 years old because of delayed psychomotor development, gait abnormalities, growth retardation and severe mental retardation. She was the first child of healthy parents, born by normal delivery after an uncomplicated pregnancy. She had her first epileptic seizures at 4 weeks old (2–3 times a day) and these seizures were refractory to treatment. Follow-up until the most recent visit, at age 6 years, indicated severe and progressive deterioration of her psychomotor development.

Figure 1

Complete deletion of exon 10 detected by MLPA (A) and confirmed by cDNA analysis (B).

Four other new DNA variants were identified, including c.1455_1460delGGCCAA (loss of lysine and alanine amino acids) in exon 12. This patient was referred to us at 3 years 2 months old by a paediatric neurologist because of developmental delay, absence of speech, seizures, and difficulty in walking (possible ataxia), though her initial psychomotor development was normal. She was the second child of healthy parents, and had a healthy 13-year-old sister. She had her first febrile seizure at the age of 11 months, and her mother reported that her development “stopped” after this episode, including with respect to her speech (possible regression). We initially classified this DNA variant as non-pathogenic because her asymptomatic mother had the same variant, and both the mother and infant showed the same cDNA and random X chromosome inactivation. However, this variant was not present in the 10 genomic databases consulted, or in the 100 normal control samples, and we therefore reclassified it as an unknown variation.

The second DNA variant was c.2389 G > A (p. Asp797Asn) in exon 17. This was inherited from the father and was therefore not a pathogenic mutation. Six other females in the healthy control group also showed this change, indicating that it represents a newly-described polymorphism in Spain.

The remaining two novel DNA changes had no clinical significance: c.−426 C > G and c.403 + 27A > G. The first was also found in five healthy female controls, and thus represented another novel polymorphism for Spain. In silico studies of the second change using the ESE Finder program [25] indicated that it was non-pathogenic. Furthermore, a similar change (c.403 + 80 G > A) in the 1,000 genomes database [24] was classified as a single nucleotide polymorphism (SNP) variant. No parental DNA was available for either of these cases.

Finally, we detected three previously reported variants. The variant c.2995 G > A (p.Val999Met), first described by Nectoux et al.[26] as likely non-pathogenic and later classified as a polymorphism [27] and SNP (rs35693326 [18]), was found in a patient whose asymptomatic mother also had this variant. This variant was also identified among the control group, and we therefore concluded that it represented a gene polymorphism. c.−391 G > T first reported by Evans et al..[12] was found in two patients and four controls. Finally, the haplotype c.145 + 17A > G; c. 3003 C > G and c. 3084 G > A, first described by Tao J et al.[28], was found in another two patients.

Discussion

Kalscheuer et al.[11] in 2003 provided the first report of mutations in the CDKL5 gene in two unrelated patients with infantile spasms and mental retardation due to two different balanced X-autosome translocations; since then, more than 80 patients with pathogenic mutations in this gene have been described [29]. The current study analysed CDKL5 mutations in 60 female patients with epilepsy, initially thought to be associated with MECP2 mutations, but who were negative for mutations and large rearrangements in this gene.

This complete genetic study of CDKL5 (sequencing of all the exons and their neighbouring sequences and analysis of gene rearrangements by MLPA) identified two new, previously undescribed pathogenic mutations, consisting of one frameshift mutation and one deletion (2/60, 3%). This rate is lower than those reported by some other authors (7,6–8%) [7,8,30], but these previous studies only included patients with precocious epilepsy, while the current study included patients undergoing MECP2 screening, but with any type of epilepsy regardless of the age of onset.

The two new mutations were found in girls with severe encephalopathy, autistic characteristics, severe deterioration of psychomotor development and onset of seizures within the first month of life, although there were some phenotypic differences between the two cases. These characteristics are in agreement with Bahi-Buisson et al.[31] and other authors [6,32], who linked mutations in the CDKL5 gene with various and overlapping phenotypes, ranging from autism and mental retardation to RTT with epilepsy phenotypes.

Recent studies have focused on better characterising the relationships between genotypes and phenotypes, given that phenotypic heterogeneity caused by mutations in CDKL5 is attributable to the nature of the mutations and their location, to inactivation of the X chromosome, and to cellular differences caused by these various mutations [31]. Some authors have failed to find any clear relationship between the type of mutation and the severity of the phenotype [31], but the most recent studies suggest that mutations in the catalytic domain of the protein (from exon 2 to exon 12; the pathogenic mutations in the present study were identified in exons 8 and 10) cause more severe clinical characteristics [7,26,32]. Specifically, Cástren et al.[33] reported that an onset of epileptic seizures within the first 6 months of life distinguished patients with CDKL5 mutations from patients with typical RTT caused by MECP2 mutations, which is in accordance with the results of the current study.

There is evidence that CDKL5 interacts with MeCP2 and modifies its phosphorylation. Castrén et al.[33] suggested that MECP2 expression levels regulate the methylation-dependent binding of CDKL5 to MeCP2 and that this interaction may explain the finding that CDKL5 mutations produce a phenotype with some features that overlap with RTT. Other authors [31,34] have speculated that the variable clinical presentations of CDKL5-related encephalopathy result from the transcriptional or translational effects of CDKL5 mutations. Further studies are required to clarify the physiological interactions between these genes.

X-chromosome inactivation is known to impact on the clinical manifestations of X-linked disorders; however, this point cannot be investigated in studies that use blood, rather than brain cells [8,31], where preferential inactivation of the mutated chromosome is believed to occur [33]. Specifically, patients with pathological mutations in the current study had normal, random inactivation of the X chromosome (58:42 and 56:44).

Finally, this study highlights the importance of analysing rearrangements of the CDKL5 gene; according to Mei et al.[35], more than 10% of the mutations in the CDKL5 gene are rearrangements. Two new pathogenic mutations were identified in the present cohort, one of which was due to a deletion detected using MLPA (50%).

Conclusions

The results of this study confirm that CDKL5 mutations are a potentially important etiological factor in neurodevelopmental disorders. Females with RTT-like phenotypes, severe encephalopathy, and very early-onset epilepsy may benefit from a complete analysis of the CDKL5 gene, in terms of both its sequence and its rearrangements. Early onset was considered to be onset before the age of 5 months [1,36], which was the most consistent clinical sign associated with CDKL5 mutations. In addition, the results demonstrate the usefulness of MLPA as a clinical screening method to establish a causative diagnosis in these patients. Overall, this study provides an important contribution to improving the understanding of the CDKL5 gene and its pathology.

Competing interests

The authors declare no conflict of interest.

Authors’ contributions

MTC, RD, FR, AGR, MJM and MALA acquired and provided clinical data and samples from their patients. HM, CMB, NP and IR produced and analysed the molecular data. HM wrote the manuscript. MIT designed, supervised and directed the project and revised the manuscript. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2350/13/68/prepub